James D. Brandt, MD

Bimatoprost insert offers noninvasive platform for early glaucoma patients A 19-month, open-label study of a novel bimatoprost, sustained-release ocular insert shows good safety and efficacy. The insert is polymer ring that sits atop the eye in the conjunctival fornix. Phase III trials are expected to begin in 2017.
Sustained-release topical rings promising for glaucomaA single bimatoprost topical ring has been shown to be effective and safe for lowering IOP over six months, according to results from a phase II study.
Drug-delivery platforms offer more options and promise for cliniciansSeven glaucoma drug delivery companies reviewed the latest data on platforms
Ocular insert overcoming glaucoma treatment challengesA bimatoprost-releasing ocular insert that rests in the conjunctival fornix (ForSight VISION5) lowered IOP in patients with ocular hypertension or glaucoma by an average of 4 to 6 mm Hg from baseline over 6 months.
CCT emerges as data point in careApplication of information may have role for enabling glaucoma screening, guiding clinical management